Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month

Article

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest expert insights in gene therapies for hemophilia, which is among the most common of these disorders.

In recent months, CGTLive has interviewed multiple experts about the various gene therapies currently in development for the treatment of hemophilia A and hemophilia B, which are among the most commonly occurring bleeding disorders.

For Bleeding Disorders Awareness Month, observed annually in the month of March by the patient and clinician communities, the CGTLive team has gathered some of our latest interviews on hemophilia gene therapies below to offer expert insight on the therapeutic progress being made for these rare disorders.

Those featured include:

  • Adam Cuker, MD, associate professor of medicine at the University of Pennsylvania
  • Steven Pipe, MD, professor of pediatric hematology/oncology at CS Mott Children’s Hospital
  • Brent Warner, president of gene therapy at Poseida Therapeutics
  • Rigoberto Garcia, MPH, executive director of the Hemophilia Foundation Southern California

Click the respective slides below to watch each expert interview.


—————————————————

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Mark Walters, MD
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
© 2024 MJH Life Sciences

All rights reserved.